Key result
Pembrolizumab therapy aggravated paraneoplastic hypereosinophilia in a patient with metastatic lung adenocarcinoma, with eosinophil counts reaching 12,100 cells/mcL before resolving upon switching to chemotherapy.
Case Report (n=1)
Pembrolizumab treatment may aggravate paraneoplastic hypereosinophilia in patients with metastatic lung adenocarcinoma.
Case of paraneoplastic eosinophilia aggravated by pembrolizumab in lung adenocarcinoma cautions against assuming ICI benefit; leaves open biomarker versus toxicity role.
There are many causes of peripheral blood eosinophilia (PBE), including allergic, infectious, rheumatic, and hematologic disorders. Solid tumor cancers, such as lung cancer, can also cause PBE, and although rare, being diagnosed with PBE in this way is associated with a worse prognosis than for lung cancer patients without PBE. Additionally, some cancer patients develop PBE when receiving treatment with immune checkpoint inhibitors (ICIs). When PBE is caused in this way, the outcome varies. On the one hand, there are reports of severe adverse events, while on the other, ICIs-induced PBE may be a predictive biomarker of better outcomes. This article reports on the case of a 66-year-old male patient with metastatic lung adenocarcinoma presenting with paraneoplastic hypereosinophilia aggravated by pembrolizumab.
No takes yet. Share an insight, caveat, or question.
Saca et al. (2024) conducted a case report in Metastatic lung adenocarcinoma (n=1). Pembrolizumab was evaluated. Pembrolizumab therapy aggravated paraneoplastic hypereosinophilia in a patient with metastatic lung adenocarcinoma, with eosinophil counts reaching 12,100 cells/mcL before resolving upon switching to chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: